										<u> </u>	IVIO I	-ORIV
SUSPECT ADVERSE REACTION REPORT												
	1	REACTION		ON								
1. PATIENT INITIALS 1a. C	COUNTRY 2. DATE OF BII		3. SEX 3a. WEI		-6 RE	ACTION	ONSET	8-12	CHE	CK ALL		
PRIVACY DOMINICA	AN REPUBLIC Day Month PRIVAC	Male Unk Day Month Year Unk						APPROPRIATE TO ADVERSE REACTION				
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas) when the dose was set the device administered more than the quantity set [Incorrect dose administered by device] when the dose was set the device administered more than the quantity set [Device delivery system issue] medication continued to come out and it came out of the patient's skin. [Accidental exposure to product related to device use] medication continued to come out and it came out of the patient's skin.							PATIENT DIED INVOLVED OR PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY					
(Continued on Additional Information Page)								, =	LIFE THREATENING			
II. SUSPECT DRUG(S) INFORMATION												
14. SUSPECT DRUG(S) (include generic name) #1) Genotropin Pen (SOMATROPIN) Solution for injection {Lot # LR7824; Exp.Dt. JUN-2027} #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection {Lot # LD7551}							A	20. DID REACTION ABATE AFTER STOPPING DRUG?				
#1) 1 mg, 1x/day (at night)			ROUTE(S) OF ADMINISTRATION 1) Unknown 2) Unknown					YES NO NA				
17. INDICATION(S) FOR USE #1) Unknown #2) Unknown							21. DID REACTION REAPPEAR AFTER REINTRODUCTION?					
#1) Unknown #). THERAPY DURATIO 1) Unknown 2) Unknown	,					YES NO NA			
	III. CONO	COMITANT D	RUG(S) AND	HIST	OR	Y		•				
	DATES OF ADMINISTRATION (exclude) e.g. diagnostics, allergies, pregnancy was represented by Type of History	rith last month of period,										
IV. MANUFACTURER INFORMATION												
24a. NAME AND ADDRESS OF MAI Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lex San Jose, COSTA RICA	26. REMARKS											
24b. MFR CONTROL NO. PV202500057328			25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.									
24c. DATE RECEIVED BY MANUFACTURER 04-JUL-2025	24d. REPORT SOURCE STUDY LITER HEALTH PROFESSIONAL 25a. REPORT TYPE	NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.										
10-JUL-2025			_									

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

[Exposure via skin contact]

the case was leaking the medication [Device leakage]

the brown gummy that indicates the doses administered did not go down and continued to stay with the air [Device failure to prime]

Case Description: This is a spontaneous report received from a Nurse and a Consumer or other non HCP, Program ID: 164974.

An 11-year-old male patient received somatropin (GENOTROPIN PEN), (Lot number: LR7824, Expiration Date: Jun2027) at 1 mg 1x/day (1 mg, 1x/day (at night)), Device Lot Number: LD7551, Device Expiration Date: Jan2027. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: INCORRECT DOSE ADMINISTERED BY DEVICE (non-serious), DEVICE DELIVERY SYSTEM ISSUE (non-serious) and all described as "when the dose was set the device administered more than the quantity set"; ACCIDENTAL EXPOSURE TO PRODUCT (non-serious), EXPOSURE VIA SKIN CONTACT (non-serious) and all described as "medication continued to come out and it came out of the patient's skin."; DEVICE LEAKAGE (non-serious), described as "the case was leaking the medication"; DEVICE FAILURE (non-serious), described as "the brown gummy that indicates the doses administered did not go down and continued to stay with the air". The action taken for somatropin was unknown.

Causality for "when the dose was set the device administered more than the quantity set", "medication continued to come out and it came out of the patient's skin.", "the case was leaking the medication" and "the brown gummy that indicates the doses administered did not go down and continued to stay with the air" was determined associated to device constituent of somatropin (malfunction).

Additional information: Reporter stated that when the dose was set the device administered more than the quantity set, it did not stay at the milligrams set, so when 1 mg was set, it did not administer that. On 23May2025 nurse reported that caregiver did not take the pen to the appointment so it was not possible to correct the turns she gives. Caregiver believed it could be applying maybe more, maybe less. As of 04Jul2025, patient's caregiver reported that when administering the medication to the patient, she inserted the vial into the case, but the case was leaking the medication, she did all the steps and the respective procedure, she eliminated the air, but she saw that it still had air. Last night, when she gave the dose to the patient and it was leaking medicine through the needle, and when she inserted it into the child, the brown gummy that indicates the doses administered did not go down and continued to stay with the air. So instead of inserting everything with the needle in place (count the 10 seconds after applying it) the medication continued to come out and it came out of the patient's skin. Reporter was given a the contact of a nurse and was advised not to administer the medication until it was checked by the nurse.

Follow-up (23May2025). This is a spontaneous follow-up report received from a nurse. Updated information included: clinical course. Follow-up (27Jun2025): Follow-up attempts are completed. Batch/lot number is not provided, and it cannot be obtained.

Follow-up (04Jul2025). This is a spontaneous follow-up report received from Consumer or other non HCP, Program ID: 164974. Updated information includes: new events of "accidental exposure to product", "exposure via skin contact", device leakage and device failure to prime, additional information.